N/A
Manufactured by DNA Labs, Inc.
1,039 FDA adverse event reports analyzed
Last updated: 2026-04-15
CALCIUM SULFATE ANHYDROUS is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by DNA Labs, Inc.. The most commonly reported adverse reactions for CALCIUM SULFATE ANHYDROUS include DIARRHOEA, PAIN, HEADACHE, FATIGUE, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CALCIUM SULFATE ANHYDROUS.
Out of 483 classified reports for CALCIUM SULFATE ANHYDROUS:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 1,039 FDA FAERS reports that mention CALCIUM SULFATE ANHYDROUS. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DIARRHOEA, PAIN, HEADACHE, FATIGUE, NAUSEA, ARTHRALGIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list DNA Labs, Inc. in connection with CALCIUM SULFATE ANHYDROUS. Always verify the specific product and NDC with your pharmacist.